

# Hanif Esmail

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4444401/hanif-esmail-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29  
papers

765  
citations

14  
h-index

27  
g-index

32  
ext. papers

1,084  
ext. citations

18.4  
avg, IF

4.33  
L-index

#	Paper	IF	Citations
29	Mind the gap - Managing tuberculosis across the disease spectrum.. <i>EBioMedicine</i> , <b>2022</b> , 103928	8.8	2
28	Tuberculosis prevalence: beyond the tip of the iceberg. <i>Lancet Respiratory Medicine</i> , <b>2022</b> , 10, 537-539	35.1	0
27	Subclinical Tuberculosis Disease-A Review and Analysis of Prevalence Surveys to Inform Definitions, Burden, Associations, and Screening Methodology. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e830-e841	11.6	35
26	Short durations of corticosteroids for hospitalised COVID-19 patients are associated with a high readmission rate. <i>Journal of Infection</i> , <b>2021</b> , 82, 276-316	18.9	9
25	Exploring a combined biomarker for tuberculosis treatment response: protocol for a prospective observational cohort study. <i>BMJ Open</i> , <b>2021</b> , 11, e052885	3	
24	Elevated N-terminal prohormone of brain natriuretic peptide among persons living with HIV in a South African peri-urban township. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3246-3251	3.7	2
23	Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 395-406	35.1	63
22	Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	18
21	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. <i>F1000Research</i> , <b>2020</b> , 9, 1109	3.6	3
20	A threat to decentralised care for drug-resistant tuberculosis. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 950-952	35.1	1
19	Individualising therapy for drug-sensitive tuberculosis. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 834-835	35.1	2
18	Spotting the old foe-revisiting the case definition for TB. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 199-203	35.1	10
17	Screening for tuberculosis: time to move beyond symptoms. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 202-204	35.1	14
16	The Immune Response to Mycobacterium tuberculosis in HIV-1-Coinfected Persons. <i>Annual Review of Immunology</i> , <b>2018</b> , 36, 603-638	34.7	52
15	Complement pathway gene activation and rising circulating immune complexes characterize early disease in HIV-associated tuberculosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E964-E973	11.5	56
14	Tuberculosis transmission during the subclinical period: could unrelated cough play a part?. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 244-246	35.1	19
13	The Wonder Years: What Can Primary School Children Teach Us About Immunity to ?. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2946	8.4	36

12	Recent progress in understanding immune activation in the pathogenesis in HIV-tuberculosis co-infection. <i>Current Opinion in HIV and AIDS</i> , <b>2018</b> , 13, 455-461	4.2	6
11	Tuberculosis is changing. <i>Lancet Infectious Diseases, The</i> , <b>2017</b> , 17, 359-361	25.5	35
10	From latent to patent: rethinking prediction of tuberculosis. <i>Lancet Respiratory Medicine, the</i> , <b>2017</b> , 5, 243-244	35.1	21
9	Tuberculosis Infectiousness and Host Susceptibility. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, S636-S643	7	46
8	QuantiferON conversion following tuberculin administration is common in HIV infection and relates to baseline response. <i>BMC Infectious Diseases</i> , <b>2016</b> , 16, 545	4	6
7	Cardio-Thoracic Ratio Is Stable, Reproducible and Has Potential as a Screening Tool for HIV-1 Related Cardiac Disorders in Resource Poor Settings. <i>PLoS ONE</i> , <b>2016</b> , 11, e0163490	3.7	2
6	Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[F]fluoro-D-glucose positron emission and computed tomography. <i>Nature Medicine</i> , <b>2016</b> , 22, 1090-1093	50.5	120
5	Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine, the</i> , <b>2015</b> , 3, 190-200	35.1	88
4	Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. <i>Drug Discovery Today</i> , <b>2012</b> , 17, 514-21	8.8	68
3	Detection and treatment of subclinical tuberculosis. <i>Tuberculosis</i> , <b>2012</b> , 92, 447-52	2.6	30
2	Is MRSA admission bacteraemia community-acquired? A case control study. <i>Journal of Infection</i> , <b>2008</b> , 56, 163-70	18.9	12
1	Before the whistle blows: developing new paradigms in tuberculosis screening to maximise benefit and minimise harm. <i>Wellcome Open Research</i> , <b>6</b> , 8	4.8	